SHRINKING PROFIT: Sanofi saw its earnings slump in the third quarter as generic competitors ate into profits of its Eloxatin cancer treatment.
DETAILS: Sanofi earned (EURO)1.6 billion ($2.1 billion) for the July-September quarter, down 20 percent from (EURO)2 billion a year earlier. Sanofi lost (EURO)448 million in sales from generic competition in the quarter, although overall sales rose 3.3 percent to (EURO)9 billion.
LOOKING AHEAD: The French drugmaker now expects its core earnings to fall 12 percent this year compared to 2011, at constant exchange rates.